Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 May 2024 | Story Leonie Bolleurs | Photo Supplied
Inaugural
At the inaugural lecture of Prof Dirk Opperman were, from the left: Prof Opperman, Prof Vasu Reddy, Prof Koos Albertyn, Head of the Department of Microbiology and Biochemistry, and Prof Paul Oberholster, Dean of the Faculty of Natural and Agricultural Sciences.

Prof Dirk Opperman, a distinguished biochemist in the Department of Microbiology and Biochemistry, recently (21 May 2024) delivered his inaugural lecture on the Bloemfontein Campus of the University of the Free State (UFS).

The title of his lecture was: Exploring, Exploiting, and Evolving Life at the Atomic Level.

Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation at the UFS, welcomed guests, stating, "An inaugural lecture is a major milestone, celebrating a life’s work that culminates in the title of professor. It marks an important chapter in an academic career, with much more to be achieved in the journey of producing important knowledge.”

He believes that an event such as this highlights the university’s pride in the achievements of its academic staff and aligns with Vision 130. “The UFS is proud to host such lectures, as they are significant moments to reveal and showcase the value of excellence in our knowledge pool in research, teaching, and innovation. As a university, we strive to make a difference through groundbreaking work, particularly in addressing society's challenges,” said Prof Reddy, emphasising that this topic truly speaks to the university’s commitment to impactful work in the hard sciences.

Deciphering the unknown

The topic of the lecture captures the essence of Prof Opperman’s research. He explains that ‘exploring’ refers to the determination of the three-dimensional structures of proteins and enzymes. ‘Exploiting’ involves the use of these enzymes to convert substrates into products of value, and ‘evolving’ pertains to mutating the DNA to change the protein, giving it different functions, activities, selectivity, or specificities.

In his lecture, he remarked that if we know the structures of these proteins and enzymes, we can explore what to do with them and how to change them. According to him, there are the unknown knowns, the unknown unknowns, and the known unknowns. “We may know of specific activities and reactions by microorganisms, but we don’t know which enzyme is responsible; similarly, we can know the reactivity of an enzyme, but not necessarily their true physiological functions. I am trying to figure out all these unknowns,” he said.

In his lecture, he also raised the question of whether AI could replace experimental determination of protein structures. "No, not yet; it is only predictions," he believes, commenting that navigating the unknown unknowns is a dangerous place in science.

Establishing the field of structural biology

Prof Opperman, born and raised in the Free State, completed his undergraduate studies at the UFS. Later, in 2008, he obtained his PhD in Biochemistry from the same university. Following his doctoral studies, he conducted postdoctoral research on directed evolution under the guidance of Prof Manfred T Reetz at the Max Planck Institute for Coal Research in Germany, one of the world’s top institutions.

In 2010, he was appointed to the Department of Microbiology and Biochemistry at the UFS, where he has since established the field of structural biology, setting up the infrastructure essential for the advancement thereof. This includes equipment, techniques, and methods for determining the three-dimensional structure of proteins. “It is done using protein crystallisation and then X-ray diffraction,” he explains. Most of these X-ray diffraction experiments are then performed at particle accelerators called synchrotrons, such as Diamond Light Source (UK), which can produce intense X-rays.

His current research explores the interface of evolutionary and structure-function relationships of biocatalysts, with a particular focus on their application in green chemistry. Prof Opperman says that understanding both the structure and the function of an enzyme allows one to manipulate it to perform other functions.

Contributing to the broader goals of sustainable development

One of the projects he is working on highlights the potential for sustainable practices in waste management. Prof Opperman is currently part of a European Research Area Network Cofund partnership on Food Systems and Climate (FOSC), which focuses on developing biocatalysts for upcycling waste. An aspect of this work involves studying enzymes that degrade feathers, thereby converting feather waste into useful products such as fertiliser.

Regarding the contribution of his research to the broader goals of sustainable development and environmental protection, he says that enzymes are the base for biotechnology and the bioeconomy. “They can be sustainably produced, the reactions are environmentally friendly, and the resulting products can be classified as natural. There’s no need to use sources that are not sustainable to extract some of these molecules from,” he explains.

His significant contributions to the field are reflected in more than 50 authored and co-authored papers, some of which are published in prestigious journals such as Science, Nature Communications, and Angewandte Chemie. As an NRF B-rated researcher, his work has received funding from various local and international organisations, including industries such as Sasol and the Global Challenges Research Fund.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept